8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 28, 2026·SEC
Scilex Holding Company(SCLX)Earnings, Financials & Key Ratios
SCLX•NASDAQ
$7.11
Price updated Jun 27, 2026
AboutScilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.Show more
- Revenue$30M-46.5%
- EBITDA-$268M-237.3%
- Net Income-$359M-392.7%
- EPS (Diluted)-36.48-87.8%
- Gross Margin49.68%-29.5%
- EBITDA Margin-884.81%-531.0%
- Operating Margin-900.09%-510.8%
- Net Margin-1185.78%-821.7%
SCLX Price & Volume
Scilex Holding Company (SCLX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Corporate Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency
"Scilex Holding Company faces a critical liquidity crisis characterized by a rapid decline in revenue from $16.4 million in 2024Q2 to $8.6 million in 2026Q1. The firm's inability to achieve operational scale is evidenced by massive quarterly losses, including a $186.5 million operating loss in 2025Q3, which continues to erode shareholder equity into a negative $249.2 million position. Investors should remain cautious as the company's reliance on dilutive financing and working capital adjustments to sustain its $106.4 million debt load suggests a high probability of further financial distress."
Verdict Logic
the company's inability to maintain positive free cash flow, evidenced by a $4.2 million burn in 2026Q1, combined with a current ratio of 0.08, indicates an imminent risk of insolvency.
SCLX Growth Metrics
Scilex Holding Company (SCLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years5.13%
3 Years-7.35%
TTM-33.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-463.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-148.53%
Return on Capital
10 Years-643.7%
5 Years-121.47%
3 Years-
Last Year-
SCLX Recent Earnings
Scilex Holding Company (SCLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (18%)●Beat Revenue 2/12 qtrs (18%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$4.76-1311.2%
$0.34
Rev
$9M-42.6%
$15M
Q2 2026
Apr 10, 2026Metric
Actual
Est
EPS
$4.60-878.7%
$0.47
Rev
$5M-60.4%
$12M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$22.17-4617.0%
$0.47
Rev
$11M-12.7%
$12M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$7.42-1709.8%
$0.41
Rev
$10M-62.3%
$26M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $4.76vs $0.34-1311.2% | $9Mvs $15M-42.6% |
| Q2 2026 | Apr 10, 2026 | $4.60vs $0.47-878.7% | $5Mvs $12M-60.4% |
| Q4 2025 | Nov 14, 2025 | $22.17vs $0.47-4617.0% | $11Mvs $12M-12.7% |
| Q3 2025 | Aug 13, 2025 | $7.42vs $0.41-1709.8% | $10Mvs $26M-62.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Scilex Holding Company (SCLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.11 | $60.37M | -0.19 | -46.54% | -1185.78% | — | — | |
| $31.69 | $1.28B | 26.63 | 27.37% | 6.35% | 29.49% | — | |
| $35.47 | $2.05B | 13.09 | 21.51% | 16.2% | 17.19% | — | |
| $9.95 | $1.38B | -0.97 | -2.75% | -43.5% | -50.65% | — | |
| $46.84 | $2.7B | -68.88 | 8.63% | -3.74% | -2.73% | — | |
| $36.59 | $1.19B | 21.15 | 23.62% | 9.41% | 26.74% | — |
Compare SCLX vs Peers
Scilex Holding Company (SCLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SCLX SEC Filings & Documents
Scilex Holding Company (SCLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SCLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SCLX Frequently Asked Questions
Scilex Holding Company (SCLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Scilex Holding Company's revenue?
Scilex Holding Company (SCLX) reported $33.9M in revenue for fiscal year 2025. This represents a 44% increase from $23.6M in 2020.
How fast is Scilex Holding Company growing?
Scilex Holding Company (SCLX) saw revenue decline by 46.5% over the past year.
Is SCLX profitable?
Scilex Holding Company (SCLX) reported a net loss of $419.7M for fiscal year 2025.
Dividend & Returns
What is Scilex Holding Company's free cash flow?
Scilex Holding Company (SCLX) had negative free cash flow of $6.6M in fiscal year 2025, likely due to heavy capital investments.